Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-017053
Filing Date
2025-06-12
Accepted
2025-06-12 18:24:33
Documents
1
Period of Report
2025-06-12

Document Format Files

Seq Description Document Type Size
1 form4-06122025_100629.html 4  
1 form4-06122025_100629.xml 4 4102
  Complete submission text file 0001415889-25-017053.txt   5670
Mailing Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Issuer) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O BLACK DIAMOND THERAPEUTICS, INC. ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address
Campbell Shannon (Reporting) CIK: 0002018966 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39200 | Film No.: 251044179